Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1987 Feb;126(2):376–383.

Abrogation of adriamycin-induced cardiotoxicity by selenium in rabbits.

N V Dimitrov, M B Hay, S Siew, D A Hudler, L J Charamella, D E Ullrey
PMCID: PMC1899583  PMID: 3826299

Abstract

Adriamycin-induced cardiomyopathy in rabbits was produced by intravenous injections of the drug with a short therapeutic schedule (3 mg/kg body wt administered as four intermittent doses). Animals receiving selenium supplementation of Adriamycin showed preservation of the normal pattern of the heart histologic picture. The protective effect of selenium was accompanied by increased selenium levels in the plasma and the heart muscle. An eventual interaction between the antitumor effect of Adriamycin and the protective effect of selenium was ruled out by in vitro experiments using the L1210 cell line. Selenium did not abrogate the antiproliferative effect of Adriamycin when the cells were treated simultaneously with both agents. The results from this study indicate that Adriamycin-induced cardiotoxicity could be prevented by selenium if the animals were pretreated with selenium, rather than simultaneous administration of both agents. The mechanism of this effect is not entirely understood.

Full text

PDF
376

Images in this article

378Figure 1
on p.378
379Figure 2
on p.379
380Figure 3
on p.380
381Figure 4
on p.381

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bachur N. R., Gordon S. L., Gee M. V. Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol Pharmacol. 1977 Sep;13(5):901–910. [PubMed] [Google Scholar]
  2. Bertazzoli C., Ghione M. Adriamycin associated cardiotoxicity: research on prevention with coenzyme Q. Pharmacol Res Commun. 1977 Mar;9(3):235–250. doi: 10.1016/s0031-6989(77)80073-8. [DOI] [PubMed] [Google Scholar]
  3. Billingham M. E., Mason J. W., Bristow M. R., Daniels J. R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978 Jun;62(6):865–872. [PubMed] [Google Scholar]
  4. Bristow M. R., Mason J. W., Billingham M. E., Daniels J. R. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J. 1981 Oct;102(4):709–718. doi: 10.1016/0002-8703(81)90096-x. [DOI] [PubMed] [Google Scholar]
  5. Bristow M. R., Thompson P. D., Martin R. P., Mason J. W., Billingham M. E., Harrison D. C. Early anthracycline cardiotoxicity. Am J Med. 1978 Nov;65(5):823–832. doi: 10.1016/0002-9343(78)90802-1. [DOI] [PubMed] [Google Scholar]
  6. Carter S. K. Adriamycin-a review. J Natl Cancer Inst. 1975 Dec;55(6):1265–1274. doi: 10.1093/jnci/55.6.1265. [DOI] [PubMed] [Google Scholar]
  7. Doroshow J. H., Locker G. Y., Myers C. E. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest. 1980 Jan;65(1):128–135. doi: 10.1172/JCI109642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jaenke R. S. An anthracycline antibiotic-induced cardiomyopathy in rabbits. Lab Invest. 1974 Mar;30(3):292–304. [PubMed] [Google Scholar]
  9. Jaenke R. S. Delayed and progressive myocardial lesions after adriamycin administration in the rabbit. Cancer Res. 1976 Aug;36(8):2958–2966. [PubMed] [Google Scholar]
  10. Kantrowitz N. E., Bristow M. R. Cardiotoxicity of antitumor agents. Prog Cardiovasc Dis. 1984 Nov-Dec;27(3):195–200. doi: 10.1016/0033-0620(84)90004-5. [DOI] [PubMed] [Google Scholar]
  11. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  12. Myers C. E., McGuire W., Young R. Adriamycin: amelioration of toxicity by alpha-tocopherol. Cancer Treat Rep. 1976 Jul;60(7):961–962. [PubMed] [Google Scholar]
  13. Olson H. M., Capen C. C. Subacute cardiotoxicity of adriamycin in the rat: biochemical and ultrastructural investigations. Lab Invest. 1977 Oct;37(4):386–394. [PubMed] [Google Scholar]
  14. Revis N. W., Marusic N. Glutathione peroxidase activity and selenium concentration in the hearts of doxorubicin-treated rabbits. J Mol Cell Cardiol. 1978 Oct;10(10):945–951. doi: 10.1016/0022-2828(78)90340-1. [DOI] [PubMed] [Google Scholar]
  15. Taylor A. L., Bulkley B. H. Acute adriamycin cardiotoxicity: morphologic alterations in isolated perfused rabbit heart. Lab Invest. 1982 Nov;47(5):459–464. [PubMed] [Google Scholar]
  16. Unverferth B. J., Magorien R. D., Balcerzak S. P., Leier C. V., Unverferth D. V. Early changes in human myocardial nuclei after doxorubicin. Cancer. 1983 Jul 15;52(2):215–221. doi: 10.1002/1097-0142(19830715)52:2<215::aid-cncr2820520206>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  17. Van Vleet J. F., Ferrans V. J., Weirich W. E. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol. 1980 Apr;99(1):13–42. [PMC free article] [PubMed] [Google Scholar]
  18. Van Vleet J. F., Greenwood L., Ferrans V. J., Rebar A. H. Effect of selenium-vitamin E on adriamycin-induced cardiomyopathy in rabbits. Am J Vet Res. 1978 Jun;39(6):997–1010. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES